8
total announcements
532041.BO · 15 min delayed
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has announced its 34th Annual General Meeting (AGM) to be held on September 30, 2026, to consider the audited standalone financial statements for the financial year ended March 31, 2026, and to approve the Scheme of Reduction of Share Capital.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has submitted its 34th Annual Report, including the notice of Annual General Meeting for the financial year 2025-26. The meeting will be held on September 30, 2026, to consider the audited standalone financial statements, re-appointment of a director, and a scheme of reduction of share capital.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has announced the outcome of its board meeting, where it has approved a scheme to reduce its issued, subscribed, and paid-up share capital under Section 66 of the Companies Act, 2013. The scheme involves the cancellation of 56,37,940 equity shares on a pro-rata basis, resulting in a reduction of the company's paid-up equity share capital from Rs. 2,05,01,600 to Rs. 92,25,720. The company also proposes to set off Rs. 1,12,75,880 out of its accumulated losses against the reduced share capital.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 31/08/2026 to consider the draft Scheme of Reorganization/Rearrangement of Share Capital of the Company.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has published un-audited financial results for the quarter ended June 30, 2026, as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net loss of Rs. 11.29 lakhs. The company's revenue from operations was Rs. 0.00 lakhs, and its total expenses were Rs. 11.68 lakhs. The statutory auditors have expressed an unmodified audit opinion.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has announced its un-audited standalone financial results for the first quarter ended June 30, 2026, with a net loss of ₹11.29 lakhs. The company's revenue from operations was ₹0.00 lakhs, and its total expenses were ₹11.68 lakhs. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2026. The statutory auditors have expressed an unmodified audit opinion.
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 31/07/2026 to consider un-audited financial results for the quarter ended 30.06.2026.